CoQ10 (Ubiquinol/Ubiquinone) — Expert Claims
Extracted from publicly available podcast transcripts and videos. Each claim is attributed and sourced.
Expert Consensus
Dose divergence: Experts recommend different amounts (100-200milligrams, 100 to 200milligrams, 420milligrams, 200-400milligrams, 200 to 400milligrams). Check the Stack & Timing tab for study-backed dosing ranges.
Claims are extracted using AI (Claude) from publicly available transcripts, each attributed to its source with an extraction-confidence rating (high / medium / low) so it can be verified, then compared against PubMed research. See how our data is made.
201 expert mentions
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The provided research corpus does not contain studies directly addressing the three specific populations Attia identifies (mitochondrial dysfunction patients, statin users, and older individuals) as p…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the 10 retrieved studies directly address the specific clinical recommendation of ubiquinol (100–200 mg with a fat-containing meal) for statin users over age 60. The available literature cover…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the 10 retrieved studies directly address the specific claim: ubiquinol supplementation at 100–200 mg with a fatty meal for statin users over age 60. The available literature covers CoQ10 in c…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the 10 retrieved studies directly address the clinical scenario described in Attia's claim: ubiquinol supplementation (100–200 mg with a fat-containing meal) specifically for statin users over…
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The provided research abstracts contain no extractable key findings, populations, or limitations, making it impossible to directly evaluate Attia's claim against the cited literature. The studies list…
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The expert's claim identifies three populations (mitochondrial dysfunction patients, statin users, older individuals) as primary CoQ10 beneficiaries. The provided literature includes a review on disor…
“three would be I think other supplementation strategies supplementation like creatine, carnitine, coq10”
CoQ10 is recommended as a supplementation strategy to support mitochondrial function and energy production.
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The provided research corpus does not contain studies directly evaluating CoQ10 supplementation outcomes stratified by the three populations Attia identifies: those with mitochondrial dysfunction, sta…
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
None of the 10 studies provided include extractable key findings, populations, or limitations, making it impossible to directly assess Attia's claim. The available literature includes reviews and meta…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the provided studies contain extractable key findings, populations, or limitations data, making it impossible to directly evaluate Attia's specific recommendation. While several relevant publi…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
The recommendation to use ubiquinol (reduced CoQ10) for statin users over 60 has partial support from the literature. PMID 30371340, a meta-analysis of RCTs on CoQ10 and statin-induced myopathy, indic…
“there's many of those that you need more of depending on your state of health or what's going on like CoQ10 if you're on a statin”
CoQ10 is a conditionally essential nutrient — one you need more of depending on your state of health — particularly if you are on a statin.
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
For patients over 60 who are on statins, he recommends ubiquinol 100 to 200 mg taken with a fat-containing meal.
The rationale for CoQ10 supplementation in statin users has biological plausibility — statins inhibit the mevalonate pathway, reducing endogenous CoQ10 synthesis — and PMID 30371340 (meta-analysis of…
“taking uh nutritional supplements that can optimize your mitochondria like the Mito Q or CoQ10 or other things that we suggested for you can be really really effective”
Nutritional supplements that optimize mitochondria, such as Mito Q or CoQ10, can be very effective for optimizing energy production, particularly during high-performance endurance activities.
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
None of the 10 listed studies provide key findings, population data, or limitations that can be directly assessed against Attia's specific recommendation. While several studies are relevant in topic (…
“taking uh nutritional supplements that can optimize your mitochondria like the Mito Q or CoQ10 or other things that we suggested for you can be really really effective”
Nutritional supplements that optimize mitochondria, such as Mito Q or CoQ10, can be very effective for optimizing energy production, particularly during high-performance endurance activities.
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
While the provided literature includes reviews and meta-analyses on CoQ10 supplementation (PMIDs 33325173, 24389208, 34129891), CoQ10 metabolism disorders (PMID 32933108), and neurological application…
“three would be I think other supplementation strategies supplementation like creatine, carnitine, coq10”
CoQ10 is recommended as a supplementation strategy to support mitochondrial function and energy production.
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
The provided research abstracts lack extractable key findings, populations, and limitations, making direct comparison impossible. While several relevant CoQ10 reviews are listed (PMIDs 33325173, 24389…
“there's many of those that you need more of depending on your state of health or what's going on like CoQ10 if you're on a statin”
CoQ10 is a conditionally essential nutrient — one you need more of depending on your state of health — particularly if you are on a statin.
“The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.”
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The claim about statin users is most directly supported: the meta-analysis (PMID: 30371340) specifically investigated CoQ10 for statin-induced myopathy in RCTs, and PMID: 32933108 and PMID: 24389208 c…
“My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat.”
For patients over 60 who are on statins, the recommendation is ubiquinol 100 to 200 milligrams taken with a fat-containing meal.
The evidence partially supports the claim. PMID 30371340 (meta-analysis of RCTs) directly addresses CoQ10 supplementation for statin-induced myopathy but notes results remain inconclusive. PMID 379716…
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trial results on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy are conflicting, with some studies showing benefit and others not.
The meta-analysis by PMID 30371340, an updated meta-analysis of randomized controlled trials on CoQ10 and statin-induced myopathy, directly addresses this claim. Its key finding notes that 'whether Co…
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy. The retrieved literature includes reviews on CoQ10 for cardiovascular disease, neurological conditio…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 10 provided research abstracts contain the Q-SYMBIO trial data or directly address CoQ10 supplementation in heart failure patients with the specific outcomes cited (cardiovascular mortalit…
“the Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.”
The Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.
None of the 10 retrieved studies correspond to the Q-SYMBIO trial or address CoQ10 supplementation in severe heart failure patients. The provided literature covers topics such as oocyte quality, ferti…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 10 retrieved studies directly address the Q-SYMBIO trial or CoQ10 supplementation in heart failure patients with cardiovascular mortality endpoints. The retrieved literature focuses on ooc…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 10 provided PubMed records correspond to or directly assess the Q-SYMBIO trial (Mortensen et al., 2014, JACC Heart Failure), which is the specific study cited by Peter Attia. The retrieved…
“doing nutrition testing on tens of thousands of people and deep analysis of minerals and vitamins and antioxidant levels and oxidative stress and CoQ10, all the things that people normally don't look at. It's so widespread like nutrient deficiency is so widespread in America.”
CoQ10 levels are commonly tested as part of comprehensive nutritional analysis, and nutrient deficiencies including CoQ10 are widespread in America.
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
None of the 10 retrieved studies directly address CoQ10 supplementation for statin-induced myopathy. The studies cover CoQ10 in contexts such as oocyte quality, ovarian aging, migraine prophylaxis, ne…
“the Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.”
The Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.
None of the 10 retrieved studies correspond to the Q-SYMBIO trial or directly address CoQ10 supplementation in severe heart failure populations. The provided literature covers topics such as oocyte qu…
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy. The retrieved literature covers CoQ10 in contexts such as oocyte quality, neurological diseases, car…
“the Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.”
The Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.
None of the 10 provided research sources directly address the Q-SYMBIO trial or CoQ10 supplementation in heart failure patients. The provided literature covers topics such as CoQ10 in neurological dis…
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy. The retrieved literature covers unrelated topics such as oocyte quality, migraine prophylaxis, ovari…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 10 provided studies directly address the Q-SYMBIO trial or CoQ10 supplementation outcomes in heart failure patients. The retrieved literature focuses on fertility, neurological disease, mi…
“doing nutrition testing on tens of thousands of people and deep analysis of minerals and vitamins and antioxidant levels and oxidative stress and CoQ10, all the things that people normally don't look at. It's so widespread like nutrient deficiency is so widespread in America.”
CoQ10 levels are commonly tested as part of comprehensive nutritional analysis, and nutrient deficiencies including CoQ10 are widespread in America.
“the Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.”
The Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.
None of the 10 published research entries provided include the Q-SYMBIO trial or any direct study on CoQ10 supplementation in heart failure patients. The available literature covers CoQ10 in contexts…
“there's actually a book a textbook a medical textbook on on drug nutrient interactions because there's so many”
The interaction between statins and CoQ10 is a documented drug-nutrient interaction, and there is even a medical textbook dedicated to drug-nutrient interactions.
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some showing benefit and others not.
The meta-analysis on CoQ10 and statin-induced myopathy (PMID: 30371340) directly addresses this claim, representing an updated synthesis of randomized controlled trials on this topic. A meta-analysis…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 10 provided studies directly reference the Q-SYMBIO trial or its specific findings regarding 420 mg/day CoQ10 reducing cardiovascular death by 43% or reducing major adverse cardiac events…
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
None of the 10 listed studies directly address CoQ10 supplementation for statin-induced myopathy. The provided research covers CoQ10 in contexts such as cardiovascular disease prevention, female subfe…
“the Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.”
The Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.
None of the 10 listed studies directly reference the Q-SYMBIO trial or provide specific findings about CoQ10 supplementation reducing major adverse cardiovascular events in heart failure patients. The…
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy. The studies cover CoQ10 in cardiovascular disease prevention, female subfertility, neurological cond…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 10 provided studies include the Q-SYMBIO trial or report its specific findings on 420 mg/day CoQ10 reducing cardiovascular death by 43% or reducing major adverse events in heart failure pa…
“I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations.”
Inconsistency in trial results may be partly due to different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
The expert's claim that inconsistent trial results may stem from different CoQ10 formulations and patient populations is plausible and indirectly supported by several studies. The pharmacokinetics rev…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 20 provided research abstracts directly reference or describe the Q-SYMBIO trial by name, nor do they provide the specific statistics cited by Attia (420 mg/day, 43% reduction in cardiovas…
“heart failure patients are a specific population with low CoQ10 levels at baseline.”
Heart failure patients in the Q-SYMBIO trial had low CoQ10 levels at baseline, which may explain why the results were striking for this specific population.
None of the 20 studies listed in the provided research directly reference the Q-SYMBIO trial or discuss baseline CoQ10 levels in heart failure patients enrolled in that specific trial. While PMID 3797…
“While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound.”
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
The expert's claim is directly supported by the meta-analysis on CoQ10 and statin-induced myopathy (PMID: 30371340), which is a strong-quality updated meta-analysis of randomized controlled trials tha…
“the Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo. That's a striking result for a supplement and warrants serious attention”
The Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.
None of the 20 provided research summaries directly reference or describe the Q-SYMBIO trial by name or report its specific 43% reduction in major adverse cardiovascular events finding. PMID 37971634…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial found that 420 mg per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
The Q-SYMBIO trial is referenced in PMID 37971634, which notes that 'recent research clearly approved the beneficial effect of Coenzyme Q10 supplementation in treatment and prevention of cardiovascula…
“I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations.”
Inconsistency in trial results may come from differences in CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
The claim that inconsistency in trial results may stem from differences in CoQ10 formulations (ubiquinol vs. ubiquinone) and patient populations is plausible and indirectly supported by the available…
“the Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.”
The Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.
None of the 10 retrieved studies directly assess the Q-SYMBIO trial or CoQ10 supplementation in heart failure patients with major adverse cardiovascular events as an endpoint. The available literature…
“The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't.”
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
The meta-analysis of randomized controlled trials on CoQ10 and statin-induced myopathy (PMID: 30371340) directly addresses this claim, explicitly stating that 'whether CoQ10 supplementation ameliorate…
“The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events.”
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
The Q-SYMBIO trial is referenced indirectly through the cardiovascular CoQ10 review (PMID: 37971634), which states that research 'clearly approved the beneficial effect of Coenzyme Q10 supplementation…
“there's actually a book a textbook a medical textbook on on drug nutrient interactions because there's so many”
The interaction between statins and CoQ10 is a documented drug-nutrient interaction, and there is even a medical textbook dedicated to drug-nutrient interactions.
“I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations.”
Attia believes part of the inconsistency in trial results comes from different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
The expert's claim that formulation differences (ubiquinol vs. ubiquinone) and patient population variability contribute to inconsistent trial results is directly addressed in PMID 37971634, a review…
“its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels.”
CoQ10 synthesis requires the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
The provided research corpus does not contain studies that directly address the mechanistic claim about statins blocking the mevalonate pathway and thereby reducing CoQ10 synthesis. While several revi…
“For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much.”
For healthy people with well-functioning mitochondria, additional CoQ10 may not provide meaningful benefit.
The claim is biologically plausible and directionally consistent with the literature, but none of the 20 studies above directly tested CoQ10 supplementation in healthy individuals with confirmed well-…
“The ubiquinol form — the reduced, active form — has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.”
The ubiquinol form of CoQ10 has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.
The available research corpus includes several reviews on CoQ10 (PMIDs 33325173, 24389208, 37971634, 34129891, 35199552) that are topically relevant, but none of the provided records include extractab…
“Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users.”
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol synthesis and CoQ10 synthesis, leading to statin-induced CoQ10 depletion that is thought to contribute to muscle pain and weakness affecting up to 10% of statin users.
None of the 10 provided studies directly address the mechanistic claim about statins inhibiting HMG-CoA reductase leading to CoQ10 depletion or statin-induced myopathy. The retrieved literature focuse…
“it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body.”
CoQ10 is a fat-soluble compound concentrated in the inner mitochondrial membrane that serves as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
Multiple reviews in the published literature directly support Rhonda Patrick's mechanistic claim. PMID 32933108 explicitly describes CoQ10's 'key role in mitochondrial oxidative phosphorylation' and i…
“The ubiquinol form — the reduced, active form — has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.”
The ubiquinol form of CoQ10 has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.
The provided research corpus does not contain studies that directly address the comparative bioavailability of ubiquinol versus ubiquinone, nor the specific mechanistic claim regarding impaired conver…
“It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.”
CoQ10 is the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.
The expert's claim is a mechanistic statement about CoQ10's role as the primary fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation. None of the 10 retrieved studies dir…
“The fat absorption point is important — CoQ10 is highly lipophilic and needs dietary fat for absorption.”
CoQ10 is highly lipophilic and needs dietary fat for absorption, making it important to take with a fat-containing meal.
None of the 10 retrieved studies directly address the pharmacokinetics or absorption mechanisms of CoQ10, particularly its lipophilicity and the effect of co-ingestion with dietary fat. The studies ar…
“CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain.”
CoQ10 (ubiquinone) sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
The expert's claim describes a specific biochemical mechanism — that CoQ10 accepts electrons from both Complex I and Complex II and donates them to Complex III in the mitochondrial electron transport…
“The ubiquinol form — the reduced, active form — has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.”
The ubiquinol form of CoQ10 has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.
None of the 10 provided studies directly address the comparative bioavailability of ubiquinol versus ubiquinone, nor the age-related impairment of ubiquinone-to-ubiquinol conversion. The closest relev…
“CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.”
CoQ10 levels decline with age, and by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.
None of the 10 retrieved studies directly address the specific claim that tissue CoQ10 levels decline 50–70% by age 70 compared to young adults. The available literature consists of reviews and meta-a…
“Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body.”
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
The expert's claim describes well-established biochemical properties of CoQ10 — its fat-solubility, endogenous synthesis, mitochondrial localization, role as an electron carrier in the respiratory cha…
“CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.”
CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults — contributing to mitochondrial dysfunction and increased oxidative stress in aging tissues.
Several reviews in the provided literature (PMIDs 24389208, 32933108, 34129891, 37102567) acknowledge that endogenous CoQ10 production declines with aging and that this coincides with age-related mito…
“Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users.”
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol and CoQ10 synthesis, and statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness (myalgia) that affects up to 10% of statin users.
The mechanistic claim that statins inhibit HMG-CoA reductase and thereby reduce CoQ10 synthesis is well-established biochemistry referenced in multiple reviews (PMIDs 24389208, 32933108, 33325173). Th…
“The ubiquinol form — the reduced, active form — has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.”
The ubiquinol form of CoQ10 has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.
The review on CoQ10 absorption and pharmacokinetics (PMID: 16551570) confirms that CoQ10 bioavailability is limited due to its hydrophobicity and large molecular weight, and that solubilized formulati…
“The ubiquinol form — the reduced, active form — has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.”
The ubiquinol form of CoQ10 has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.
None of the 10 provided studies contain extractable key findings relevant to directly evaluating the claim about ubiquinol vs. ubiquinone bioavailability or age-related conversion impairment. While PM…
“Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users.”
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol synthesis and CoQ10 synthesis, leading to statin-induced CoQ10 depletion that is thought to contribute to muscle pain and weakness affecting up to 10% of statin users.
None of the 10 provided studies directly address the mechanistic claim about statins inhibiting HMG-CoA reductase, statin-induced CoQ10 depletion, or statin-associated myopathy. The retrieved literatu…
“Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body.”
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
Multiple reviews in the provided literature directly corroborate Rhonda Patrick's mechanistic claims. PMID 32933108 explicitly states CoQ10 has 'vital functions in all cells' and a 'key role in mitoch…
“CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.”
CoQ10 levels decline with age, and by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.
Multiple reviews in the provided literature (PMIDs 24389208, 32933108, 34129891, 35199552) consistently acknowledge that endogenous CoQ10 production declines with aging and that this decline coincides…
“The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.”
The heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ.
Several reviews in the provided literature (PMIDs 24389208, 37971634, 34129891) discuss CoQ10's critical role in mitochondrial bioenergetics and its clinical relevance in cardiovascular disease, impli…
“Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users.”
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol synthesis and CoQ10 synthesis, leading to statin-induced CoQ10 depletion that is thought to contribute to muscle pain and weakness affecting up to 10% of statin users.
The mechanistic claim that statins inhibit HMG-CoA reductase and thereby reduce CoQ10 synthesis is well-established biochemistry referenced in multiple reviews above (PMIDs 33325173, 24389208, 3293310…
“CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain.”
CoQ10 sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
Multiple reviews in the provided literature confirm CoQ10's role as an electron and proton carrier in the mitochondrial respiratory chain. PMID 24389208 explicitly describes CoQ10 as an 'electron and…
“The fat absorption point is important — CoQ10 is highly lipophilic and needs dietary fat for absorption.”
CoQ10 is highly lipophilic and needs dietary fat for absorption, making it important to take with a fat-containing meal.
The claim that CoQ10 is highly lipophilic and benefits from co-administration with dietary fat is a well-established pharmacokinetic principle consistent with the general literature on CoQ10 formulati…
“I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations.”
Attia believes part of the inconsistency in trial results comes from different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
Attia's mechanistic claim that formulation differences (ubiquinol vs. ubiquinone) and patient population heterogeneity contribute to inconsistent CoQ10 trial results has biological plausibility suppor…
“It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.”
CoQ10 is the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.
The claim that CoQ10 is the primary fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation is a mechanistic biochemistry claim, but none of the 10 retrieved studies directl…
“Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body.”
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
The expert's mechanistic claim about CoQ10 as a fat-soluble antioxidant and electron carrier in the mitochondrial respiratory chain is consistent with foundational biochemistry referenced across multi…
“It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.”
CoQ10 is the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.
None of the 10 retrieved studies directly address the mechanistic claim that CoQ10 is the 'main' fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation. The studies focus o…
“I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations.”
Attia believes part of the inconsistency in trial results comes from different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
Attia's claim that formulation differences (ubiquinol vs. ubiquinone) and patient population heterogeneity contribute to inconsistent CoQ10 trial results is mechanistically plausible and partially sup…
“whether it's CoQ10 or torine, these are so these are not considered essential vitamins or nutrients, but but they're I call these conditionally essential because of the increased load of stress of toxins”
CoQ10 is not considered a classic essential vitamin or nutrient, but Hyman considers it 'conditionally essential' due to increased loads of stress and toxins.
“It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.”
CoQ10 is the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.
Multiple reviews in the provided literature (PMIDs 35199552, 32933108, 16551570) confirm CoQ10 is described as 'the only endogenous lipid antioxidant' and a key component of cellular membranes with an…
“its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels.”
CoQ10 synthesis uses the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
The mechanistic claim that statins block the mevalonate pathway and thereby reduce CoQ10 synthesis is a well-established pharmacological principle referenced implicitly in multiple reviews provided. P…
“The ubiquinol form — the reduced, active form — has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.”
The ubiquinol form of CoQ10 has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.
None of the 10 provided studies contain extractable key findings, populations, or limitations that directly address the bioavailability comparison between ubiquinol and ubiquinone, or the age-related…
“The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.”
The heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ.
None of the 10 listed studies directly address the mechanistic claim that the heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ. While several r…
“It it it interrupts the enzyme that makes cholesterol. That same enzyme makes HMG COA reductase makes CoQ10. So you're blocking CoQ10. What is CoQ10? It's essential nutrient for making energy from food. And it and and your mitochondrial function. So people get muscle injury and muscle pain and and elevated what we call CPK which is damaged muscle enzymes because of this and doctors don't recommend usually CoQ10 with statins.”
Statins block the HMG-CoA reductase enzyme, which is the same enzyme that produces CoQ10, thereby depleting CoQ10 levels. Because CoQ10 is essential for making energy from food and for mitochondrial function, statin users who are CoQ10-depleted can experience muscle injury, muscle pain, and elevated CPK (damaged muscle enzymes). Doctors typically do not recommend CoQ10 alongside statins.
“CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.”
CoQ10 levels decline with age, and by age 70 tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress.
The general mechanistic claim that CoQ10 declines with age and contributes to mitochondrial dysfunction and oxidative stress is broadly consistent with multiple reviews in the provided literature. For…
“Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users.”
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol synthesis and CoQ10 synthesis, leading to statin-induced CoQ10 depletion that is thought to contribute to muscle pain and weakness affecting up to 10% of statin users.
None of the 10 provided studies directly address the mechanistic claim about statins inhibiting HMG-CoA reductase and causing CoQ10 depletion linked to myopathy. The retrieved literature focuses on Co…
“heart failure patients are a specific population with low CoQ10 levels at baseline.”
Heart failure patients are a specific population with low CoQ10 levels at baseline, which may explain the striking Q-SYMBIO results.
The provided literature broadly supports CoQ10's role in mitochondrial bioenergetics and its clinical relevance in cardiovascular disease. PMID 37971634 (review) notes beneficial effects of CoQ10 supp…
“The fat absorption point is important — CoQ10 is highly lipophilic and needs dietary fat for absorption.”
CoQ10 is highly lipophilic and needs dietary fat for absorption, making it important to take with a fat-containing meal.
None of the 10 retrieved studies directly address the pharmacokinetic claim that CoQ10 requires co-ingestion with dietary fat for optimal absorption. The studies cover topics such as cardiovascular di…
“CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.”
CoQ10 levels decline with age, and by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.
None of the 10 provided studies include key findings, populations, or limitations data that would allow direct evaluation of the specific claim that CoQ10 declines 50-70% by age 70. While several revi…
“The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.”
The heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ.
None of the 10 provided studies directly address the claim that the heart is particularly vulnerable to CoQ10 depletion due to its high energy demands. The studies cover topics such as oocyte quality,…
“The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.”
The heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ.
None of the 10 listed studies provide key findings, populations, or limitations data that directly address the mechanistic claim that the heart is particularly vulnerable to CoQ10 depletion due to its…
“The fat absorption point is important — CoQ10 is highly lipophilic and needs dietary fat for absorption.”
CoQ10 is highly lipophilic and needs dietary fat for absorption, making it important to take with a fat-containing meal.
The pharmacokinetics review (PMID: 16551570) directly addresses CoQ10's lipophilic nature and absorption characteristics, confirming that CoQ10 is highly hydrophobic with a large molecular weight, mak…
“Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body.”
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
The expert's claim about CoQ10's biochemical role as a fat-soluble electron carrier in the mitochondrial respiratory chain and as an antioxidant is well-established mechanistic biochemistry. Multiple…
“The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.”
The heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ.
None of the 10 retrieved studies directly address the claim that the heart is particularly vulnerable to CoQ10 depletion due to its high energy demands. The available literature focuses on fertility,…
“Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users.”
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol synthesis and CoQ10 synthesis, leading to statin-induced CoQ10 depletion that is thought to contribute to muscle pain and weakness affecting up to 10% of statin users.
None of the 10 provided studies directly address the mechanistic claim about statins inhibiting HMG-CoA reductase and causing CoQ10 depletion, nor do they assess the prevalence of statin-induced myopa…
“its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels.”
CoQ10 synthesis requires the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
The provided research abstracts contain no key findings, populations, or limitations data — all fields are listed as 'None' — making it impossible to directly evaluate the mechanistic claim from the p…
“CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain.”
CoQ10 (ubiquinone) sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
The mechanistic claim about CoQ10's role in the mitochondrial electron transport chain is consistent with well-established biochemistry referenced across multiple reviews in the literature provided. P…
“The fat absorption point is important — CoQ10 is highly lipophilic and needs dietary fat for absorption.”
CoQ10 is highly lipophilic and needs dietary fat for absorption, making it important to take with a fat-containing meal.
While Peter Attia's claim about CoQ10's lipophilicity and the need for dietary fat co-administration is pharmacologically plausible and widely cited in clinical practice, none of the 10 provided studi…
“The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.”
The heart is particularly vulnerable to CoQ10 depletion because it has the highest energy demands of any organ.
The cardiovascular review (PMID: 37971634) acknowledges beneficial effects of CoQ10 in heart failure and cardiovascular disease, implicitly supporting the heart's high energy dependence on CoQ10. The…
“I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations.”
Attia believes part of the inconsistency in trial results comes from different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
Attia's claim that formulation differences (ubiquinol vs. ubiquinone) and patient population heterogeneity contribute to inconsistent CoQ10 trial results is conceptually supported by the literature av…
“CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain.”
CoQ10 (ubiquinone) sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
The expert's claim is a standard biochemical mechanistic statement about CoQ10's role in the mitochondrial electron transport chain (ETC). While this claim is well-established in biochemistry textbook…
“I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations.”
Attia believes part of the inconsistency in trial results comes from different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
The claim that formulation differences (ubiquinol vs. ubiquinone) contribute to trial inconsistency is directly addressed in PMID 37971634, a review comparing ubiquinone and ubiquinol supplementation…
“It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.”
CoQ10 is the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.
The provided research corpus consists entirely of reviews and meta-analyses focused on clinical applications of CoQ10 (cardiovascular, fertility, neurological, bipolar disorder) rather than directly e…
“its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels.”
CoQ10 synthesis requires the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
The expert's claim concerns a specific biochemical mechanism — that statins inhibit the mevalonate pathway and thereby reduce CoQ10 synthesis and plasma/tissue levels. None of the 10 provided studies…
“its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels.”
CoQ10 synthesis requires the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
The mechanistic claim that statins block the mevalonate pathway and thereby reduce CoQ10 synthesis is a well-established biochemical principle referenced in the literature, and PMID 30371340 (a meta-a…
“The fat absorption point is important — CoQ10 is highly lipophilic and needs dietary fat for absorption.”
CoQ10 is highly lipophilic and needs dietary fat for absorption, making it important to take with a fat-containing meal.
While the claim that CoQ10 is highly lipophilic and benefits from co-administration with dietary fat is a well-established pharmacokinetic principle referenced in general CoQ10 literature, none of the…
“CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.”
CoQ10 levels decline with age, and by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.
None of the provided studies contain key findings, populations, or limitations data, making it impossible to directly verify or refute the specific claim that CoQ10 levels decline 50–70% by age 70. Wh…
“The ubiquinol form — the reduced, active form — has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.”
The ubiquinol form of CoQ10 has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.
The provided research abstracts contain no extractable key findings, populations, or limitations — all relevant fields are null. While PMID 37971634 is a review specifically comparing ubiquinone and u…
“CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain.”
CoQ10 (ubiquinone) sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
The expert's claim describes a well-established biochemical mechanism: CoQ10 (ubiquinone) acts as a mobile electron carrier in the inner mitochondrial membrane, accepting electrons from both Complex I…
“Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body.”
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
The claim describes well-established biochemistry of CoQ10 that is consistent with mechanistic information referenced across multiple reviews in the provided literature. Reviews such as PMID 33325173,…
“The fat absorption point is important — CoQ10 is highly lipophilic and needs dietary fat for absorption.”
CoQ10 is highly lipophilic and needs dietary fat for absorption, making it important to take with a fat-containing meal.
None of the 10 provided studies directly address CoQ10 absorption mechanisms or the impact of co-ingestion with dietary fat on bioavailability. The retrieved literature focuses on clinical outcomes in…
“I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations.”
Attia believes part of the inconsistency in trial results comes from different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
Attia's mechanistic claim about formulation differences (ubiquinol vs. ubiquinone) contributing to trial inconsistency is directly addressed by PMID 37971634, a review specifically comparing these two…
“Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users.”
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol synthesis and CoQ10 synthesis, leading to statin-induced CoQ10 depletion that is thought to contribute to muscle pain and weakness affecting up to 10% of statin users.
None of the 10 listed studies directly address the mechanistic claim about statins inhibiting HMG-CoA reductase leading to CoQ10 depletion and statin-induced myopathy. The available literature covers…
“Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body.”
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
The expert's claim describes well-established biochemistry regarding CoQ10's role as a fat-soluble electron carrier in the mitochondrial respiratory chain and as an antioxidant. Several reviews in the…
“CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain.”
CoQ10 (ubiquinone) sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
The expert's claim describes a specific mechanistic role of CoQ10 in the mitochondrial electron transport chain — acting at the junction of Complex I and Complex II to shuttle electrons to Complex III…
“its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels.”
CoQ10 synthesis requires the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
The expert's claim is a well-established biochemical mechanism — statins inhibit HMG-CoA reductase in the mevalonate pathway, which is also required for CoQ10 synthesis, thereby reducing plasma and ti…
“It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.”
CoQ10 is the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.
The expert's claim that CoQ10 is the *main* fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation is a mechanistic assertion that requires direct biochemical evidence to e…
“Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users.”
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol synthesis and CoQ10 synthesis, leading to statin-induced CoQ10 depletion that is thought to contribute to muscle pain and weakness affecting up to 10% of statin users.
The provided research corpus does not contain studies directly evaluating the mechanistic claim about statin-induced HMG-CoA reductase inhibition leading to CoQ10 depletion and myopathy. While several…
“its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels.”
CoQ10 synthesis requires the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
While the mechanistic claim that statins inhibit the mevalonate pathway and thereby reduce CoQ10 synthesis is well-established biochemistry, none of the 10 listed studies directly address or test this…
“Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users.”
Statins inhibit HMG-CoA reductase, which is needed for both cholesterol synthesis and CoQ10 synthesis, meaning statin use can deplete CoQ10 levels.
The mechanistic claim that statins inhibit HMG-CoA reductase and thereby reduce CoQ10 synthesis is well-established biochemistry referenced in PMID 30371340 (a strong meta-analysis on CoQ10 and statin…
“It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.”
CoQ10 is the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.
None of the 10 provided studies contain extractable key findings, populations, or limitations data, making direct evidentiary comparison impossible. While CoQ10's role as a fat-soluble antioxidant in…
“The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.”
The heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ.
None of the 10 retrieved studies directly address the claim that the heart is particularly vulnerable to CoQ10 depletion due to its high energy demands. The studies cover topics such as CoQ10 metaboli…
“CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.”
CoQ10 levels decline with age, and by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.
The expert's claim that CoQ10 tissue levels decline 50–70% by age 70 is a specific mechanistic assertion requiring direct measurement studies in aging human tissues. None of the 10 provided studies ad…
“whether it's CoQ10 or torine, these are so these are not considered essential vitamins or nutrients, but but they're I call these conditionally essential because of the increased load of stress of toxins”
CoQ10 is not considered a classic essential vitamin or nutrient, but Hyman considers it 'conditionally essential' due to increased loads of stress and toxins.
“CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain.”
CoQ10 (ubiquinone) sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
None of the 10 listed studies provide direct evidence specifically addressing CoQ10's mechanistic role at the junction of Complex I and Complex II in the mitochondrial electron transport chain. The cl…
“I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations.”
Attia believes part of the inconsistency in trial results comes from different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
Attia's mechanistic claim that formulation differences (ubiquinol vs. ubiquinone) and patient population heterogeneity contribute to inconsistent CoQ10 trial results is plausible and directionally sup…
“While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound.”
CoQ10 supplementation is prescribed for people on statins because statin-induced CoQ10 depletion is thought to contribute to muscle pain and weakness (myalgia) affecting up to 10% of statin users, though evidence that it fully reverses statin myopathy is mixed.
The expert's mechanistic claim that statins deplete CoQ10 and that this may contribute to myalgia is consistent with the rationale described in PMID 30371340, a meta-analysis of randomized controlled…
“It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.”
CoQ10 is the main fat-soluble antioxidant that protects mitochondrial membranes from lipid peroxidation.
Multiple reviews in the literature (PMIDs 35199552, 32933108, 24389208) confirm that CoQ10 is the only endogenously synthesized lipid-soluble antioxidant present in all cellular membranes, supporting…
“Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body.”
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
The expert's claim describes well-established biochemistry of CoQ10 — its fat-solubility, endogenous synthesis, mitochondrial localization, role as an electron carrier in the respiratory chain, and an…
“its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels.”
CoQ10 synthesis requires the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
The expert's claim is a well-established biochemical mechanistic statement about the mevalonate pathway and statin-induced CoQ10 reduction. However, none of the 10 provided studies directly address th…
“CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.”
CoQ10 levels decline with age, and by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.
None of the 10 retrieved studies directly address the specific claim that tissue CoQ10 levels decline 50–70% by age 70 compared to young adults. The provided studies focus on CoQ10 supplementation eff…
“The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.”
The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.
Multiple reviews in the provided literature (PMIDs 24389208, 37971634, 34129891) confirm CoQ10's critical role in mitochondrial bioenergetics and oxidative phosphorylation, and cardiovascular-focused…
“CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.”
CoQ10 levels decline with age, and by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.
While the expert's claim about age-related CoQ10 decline is a widely cited concept in the CoQ10 literature, none of the 10 provided studies directly report quantitative data on the magnitude of tissue…
“The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion.”
The heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ.
None of the 10 retrieved studies directly address the claim that the heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ. The available publicatio…
“Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body.”
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as one of the most important fat-soluble antioxidants in the body.
Multiple reviews in the provided literature directly corroborate Rhonda Patrick's mechanistic description of CoQ10. PMID 32933108 explicitly confirms CoQ10's vital mitochondrial and extramitochondrial…
“It it it interrupts the enzyme that makes cholesterol. That same enzyme makes HMG COA reductase makes CoQ10. So you're blocking CoQ10. What is CoQ10? It's essential nutrient for making energy from food. And it and and your mitochondrial function. So people get muscle injury and muscle pain and and elevated what we call CPK which is damaged muscle enzymes because of this and doctors don't recommend usually CoQ10 with statins.”
Statins block the HMG-CoA reductase enzyme, which is the same enzyme that produces CoQ10, thereby depleting CoQ10 levels. Because CoQ10 is essential for making energy from food and for mitochondrial function, statin users who are CoQ10-depleted can experience muscle injury, muscle pain, and elevated CPK (damaged muscle enzymes). Doctors typically do not recommend CoQ10 alongside statins.
“CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain.”
CoQ10 (ubiquinone) sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
The expert's claim describes a specific biochemical mechanism — that CoQ10 accepts electrons from both Complex I and Complex II and donates them to Complex III in the mitochondrial electron transport…
“I supplement with ubiquinol at 100 to 200 milligrams with fat-containing meals.”
Rhonda Patrick personally supplements with ubiquinol at 100 to 200 milligrams taken with fat-containing meals.
The claim is a personal anecdote about Rhonda Patrick's individual supplementation practice (100–200 mg ubiquinol with fat-containing meals), which by nature cannot be directly supported or contradict…
“I went on a statin at age 35. It was not recommended to go on CoQ10 at the time. No. Uh it ended up finding about finding it myself, right? Take Mitoq now. You know, it's just one of those things that feels essential.”
Hyman personally went on a statin at age 35 and was not initially recommended to take CoQ10 alongside it, but later discovered this on his own and now takes MitoQ, which he describes as feeling essential.
“In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial.”
In Attia's clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
None of the 10 provided studies directly address CoQ10 (ubiquinol) supplementation for statin-induced myalgia, which is the specific claim being made. The studies cover topics such as fertility, neuro…
“In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial.”
In his clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
PMID 30371340, a meta-analysis of randomized controlled trials specifically examining CoQ10 supplementation for statin-induced myopathy, is directly relevant but concludes that the evidence remains un…
“I supplement with ubiquinol at 100 to 200 milligrams with fat-containing meals.”
Rhonda Patrick personally supplements with ubiquinol at 100 to 200 milligrams taken with fat-containing meals.
The claim is a personal anecdote about Rhonda Patrick's own supplementation regimen (100–200 mg ubiquinol with fat-containing meals), which by definition cannot be directly supported or contradicted b…
“In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial.”
In Attia's clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
None of the 10 published studies provided contain extractable key findings, populations, or limitations data, making direct comparison impossible. The available papers include reviews on CoQ10 supplem…
“In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial.”
In Attia's clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
The meta-analysis on CoQ10 and statin-induced myopathy (PMID: 30371340) directly addresses this claim, examining randomized controlled trials on whether CoQ10 supplementation ameliorates statin-induce…
“I supplement with ubiquinol at 100 to 200 milligrams with fat-containing meals.”
Rhonda Patrick personally supplements with ubiquinol at 100 to 200 milligrams taken with fat-containing meals.
The claim is a personal anecdote about Rhonda Patrick's own supplementation regimen, which cannot be directly 'supported' or 'contradicted' by research. However, the research literature does address t…
“I supplement with ubiquinol at 100 to 200 milligrams with fat-containing meals.”
Rhonda Patrick personally supplements with ubiquinol at 100 to 200 milligrams taken with fat-containing meals.
The claim is a personal anecdote about Rhonda Patrick's own supplementation practice, not a testable scientific assertion per se. However, the research evidence does support the general rationale behi…
“In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial.”
In Attia's clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
The provided research corpus does not contain any studies directly evaluating CoQ10 or ubiquinol supplementation for statin-induced myalgia. While several reviews on CoQ10 clinical applications (PMIDs…
“In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial.”
In Attia's clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
None of the 10 listed studies directly address CoQ10 or ubiquinol supplementation for statin-induced myalgia. The available literature includes reviews on CoQ10 for cardiovascular disease, neurologica…
“I supplement with ubiquinol at 100 to 200 milligrams with fat-containing meals.”
Rhonda Patrick personally supplements with ubiquinol at 100 to 200 milligrams taken with fat-containing meals.
The claim is a personal anecdote about Rhonda Patrick's own supplementation practice (100–200 mg ubiquinol taken with fat-containing meals), not a scientific claim about efficacy in a population. The…
“I supplement with ubiquinol at 100 to 200 milligrams with fat-containing meals.”
Rhonda Patrick personally supplements with ubiquinol at 100 to 200 milligrams taken with fat-containing meals.
The claim is a personal anecdote about Rhonda Patrick's own supplementation practice, not a scientific claim about efficacy. The practice of taking ubiquinol (reduced CoQ10) with fat-containing meals…
“I went on a statin at age 35. It was not recommended to go on CoQ10 at the time. No. Uh it ended up finding about finding it myself, right? Take Mitoq now. You know, it's just one of those things that feels essential.”
Hyman personally went on a statin at age 35 and was not initially recommended to take CoQ10 alongside it, but later discovered this on his own and now takes MitoQ, which he describes as feeling essential.
“In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial.”
In Attia's clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
None of the 10 retrieved studies directly address CoQ10 (ubiquinol) supplementation for statin-induced myalgia. The available literature covers CoQ10 in contexts such as neurological disease, cardiova…
“I supplement with ubiquinol at 100 to 200 milligrams with fat-containing meals.”
Rhonda Patrick personally supplements with ubiquinol at 100 to 200 milligrams taken with fat-containing meals.
The claim is a personal anecdote about Rhonda Patrick's own supplementation regimen (100–200 mg ubiquinol with fat-containing meals), not a scientific assertion about efficacy in a population. The pro…
“In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial.”
In his clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 mg of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
The meta-analysis on CoQ10 and statin-induced myopathy (PMID: 30371340) directly addresses this claim, examining randomized controlled trials on whether CoQ10 supplementation ameliorates statin-induce…
“In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial.”
In Attia's clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
None of the 10 provided studies directly address CoQ10 (ubiquinol) supplementation for statin-induced myalgia, which is the specific clinical scenario Attia describes. The retrieved literature covers…
“For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much.”
For healthy people, the case for CoQ10 is weaker; if mitochondria are functioning well, additional CoQ10 may not do much.
The provided research abstracts contain no extractable key findings, populations, or limitations, making direct comparison impossible. The studies listed focus predominantly on specific clinical condi…
“heart failure patients shouldn't change their medication without medical supervision.”
Heart failure patients should not change their medication without medical supervision, even given the striking Q-SYMBIO trial result.
None of the 10 provided studies directly address the Q-SYMBIO trial, heart failure management, or the specific caution about medication changes under medical supervision. The provided literature focus…
“While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound.”
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy. The retrieved literature covers CoQ10 in contexts such as oocyte quality, cardiovascular disease, mi…
“While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound.”
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
The meta-analysis on CoQ10 and statin-induced myopathy (PMID: 30371340) directly addresses this claim, being an updated meta-analysis of randomized controlled trials that explicitly acknowledges uncer…
“heart failure patients shouldn't change their medication without medical supervision.”
Heart failure patients should not change their medication without medical supervision, even given the striking Q-SYMBIO trial result.
The expert's caution about not changing heart failure medication without medical supervision is clinically sound and aligns with the general tenor of the CoQ10 cardiovascular literature. The review on…
“For a supplement, that's a striking result, though heart failure patients are a specific population with low CoQ10 levels at baseline.”
Attia notes the Q-SYMBIO result is striking for a supplement, but qualifies that heart failure patients are a specific population with low CoQ10 levels at baseline.
The provided research corpus does not include the Q-SYMBIO trial itself, nor do any of the listed studies provide key findings, population details, or limitations that could be used to directly evalua…
“While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound.”
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy (statin myopathy). The available literature covers CoQ10 in cardiovascular disease prevention, fertil…
“heart failure patients shouldn't change their medication without medical supervision.”
Heart failure patients should not change their medication without medical supervision, even given the striking Q-SYMBIO trial result.
None of the 10 provided studies directly address the Q-SYMBIO trial, heart failure management, or the specific caution about medication changes in heart failure patients. The available literature cove…
“For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much.”
For healthy people, the case for CoQ10 is weaker; if mitochondria are functioning well, additional CoQ10 may not do much.
None of the provided studies include key findings, populations, or limitations data, making it impossible to directly evaluate Attia's claim against the specific research. The available studies (PMIDs…
“While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound.”
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy. The retrieved literature focuses on fertility, cardiovascular disease, neurological conditions, and…
“While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound.”
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy (statin myopathy). The available literature covers CoQ10 in contexts such as cardiovascular disease p…
“While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound.”
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy (statin myopathy). The retrieved literature covers CoQ10 in contexts such as oocyte quality, cardiova…
“For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much.”
For healthy people, the case for CoQ10 is weaker; if mitochondria are functioning well, additional CoQ10 may not do much.
The expert's caution about CoQ10 in healthy individuals is biologically plausible and indirectly supported by the literature, but no studies in the provided evidence directly test CoQ10 supplementatio…
“heart failure patients shouldn't change their medication without medical supervision.”
Heart failure patients should not change their medication without medical supervision, even given the striking Q-SYMBIO trial result.
None of the 10 provided studies address heart failure, the Q-SYMBIO trial, or medication management in cardiac patients. The provided literature focuses on fertility, ovarian aging, migraine prophylax…
“heart failure patients shouldn't change their medication without medical supervision.”
Heart failure patients should not change their medication without medical supervision, even given the striking Q-SYMBIO trial result.
None of the 10 provided studies directly address the Q-SYMBIO trial or the specific clinical guidance that heart failure patients should not alter medications without medical supervision. The listed l…
“For a supplement, that's a striking result, though heart failure patients are a specific population with low CoQ10 levels at baseline.”
Attia notes the Q-SYMBIO result is striking for a supplement, but qualifies that heart failure patients are a specific population with low CoQ10 levels at baseline.
None of the 10 provided studies directly address the Q-SYMBIO trial, heart failure populations, or CoQ10 levels in cardiac patients. The available literature covers CoQ10 in contexts such as fertility…
“While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound.”
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
None of the 10 provided studies directly address CoQ10 supplementation and statin-induced myopathy (statin myopathy). The retrieved literature covers CoQ10 in contexts such as oocyte quality, fertilit…
“For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much.”
For healthy people, the case for CoQ10 is weaker; if mitochondria are functioning well, additional CoQ10 may not do much.
The published research provided contains no extractable key findings, populations, or limitations for any of the 10 studies listed, making it impossible to directly evaluate Attia's claim that CoQ10 s…
“For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much.”
For healthy people, the case for CoQ10 is weaker; if mitochondria are functioning well, additional CoQ10 may not do much.
The provided research corpus does not contain studies specifically examining CoQ10 supplementation in healthy, mitochondrially-competent individuals. The available studies focus on clinical population…
“For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much.”
For healthy people, the case for CoQ10 is weaker; if mitochondria are functioning well, additional CoQ10 may not do much.
The provided research abstracts contain no extractable key findings, populations, or limitations — all relevant fields are listed as 'None.' While the study types (reviews, systematic reviews, meta-an…
“For a supplement, that's a striking result, though heart failure patients are a specific population with low CoQ10 levels at baseline.”
Attia notes the Q-SYMBIO result is striking for a supplement, but qualifies that heart failure patients are a specific population with low CoQ10 levels at baseline.
None of the 10 provided studies directly address the Q-SYMBIO trial, heart failure populations, or the specific claim that heart failure patients have low CoQ10 levels at baseline. The literature prov…
“For a supplement, that's a striking result, though heart failure patients are a specific population with low CoQ10 levels at baseline.”
Attia notes the Q-SYMBIO result is striking for a supplement, but qualifies that heart failure patients are a specific population with low CoQ10 levels at baseline.
None of the 10 provided studies directly address the Q-SYMBIO trial, CoQ10 supplementation in heart failure patients, or the specific claim about baseline CoQ10 deficiency in that population. The avai…
“For a supplement, that's a striking result, though heart failure patients are a specific population with low CoQ10 levels at baseline.”
Attia notes the Q-SYMBIO result is striking for a supplement, but qualifies that heart failure patients are a specific population with low CoQ10 levels at baseline.
None of the 10 provided studies directly evaluate or report findings from the Q-SYMBIO trial, nor do they provide specific data on baseline CoQ10 levels in heart failure patients as a population. The…
“For a supplement, that's a striking result, though heart failure patients are a specific population with low CoQ10 levels at baseline.”
Attia notes the Q-SYMBIO result is striking for a supplement, but qualifies that heart failure patients are a specific population with low CoQ10 levels at baseline.
The provided literature does not directly include the Q-SYMBIO trial, so Attia's specific reference to that result cannot be directly verified from these sources. However, PMID 37971634 (a review on C…
“heart failure patients shouldn't change their medication without medical supervision.”
Heart failure patients should not change their medication without medical supervision when considering CoQ10 supplementation.
The claim is a general safety/medical caution rather than a specific efficacy claim, making it difficult to directly test against the provided literature. The cardiovascular review (PMID: 37971634) no…
“For a supplement, that's a striking result, though heart failure patients are a specific population with low CoQ10 levels at baseline.”
Attia notes the Q-SYMBIO result is striking for a supplement, but qualifies that heart failure patients are a specific population with low CoQ10 levels at baseline.
None of the 10 provided studies directly address the Q-SYMBIO trial, heart failure populations, or the specific claim that heart failure patients have low CoQ10 levels at baseline. The provided litera…
“For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much.”
For healthy people, the case for CoQ10 is weaker; if mitochondria are functioning well, additional CoQ10 may not do much.
The provided research abstracts lack extractable key findings, populations, and limitations, making direct comparison impossible. The studies available focus on specific clinical conditions (CoQ10 def…
“heart failure patients shouldn't change their medication without medical supervision.”
Heart failure patients should not change their medication without medical supervision, even given the striking Q-SYMBIO trial result.
The expert's claim is a standard medical safety caution advising heart failure patients not to alter medications without physician oversight, specifically in the context of the Q-SYMBIO trial. None of…
“heart failure patients shouldn't change their medication without medical supervision.”
Heart failure patients should not change their medication without medical supervision, even given the striking Q-SYMBIO trial result.
None of the 10 provided studies directly address the Q-SYMBIO trial, heart failure management, or the specific caution about medication changes in heart failure patients. The available literature cove…
“you look at all your nutritional status right the B vitamins vitamin D vitamin E magnesium zinc copper CoQ10 lipoic acid Omega-3s”
CoQ10 is listed as a nutritional marker worth measuring when assessing overall health status, alongside other vitamins and nutrients.
“CoQ10 is one of the supplements I think about seriously from a mitochondrial function standpoint, and it has particular clinical relevance for my patients who are on statins.”
CoQ10 is a supplement Attia thinks about seriously from a mitochondrial function standpoint, with particular clinical relevance for patients on statins.
The claim that CoQ10 has clinical relevance for mitochondrial function is broadly consistent with the literature, as multiple reviews (PMIDs 24389208, 33325173, 34129891) address CoQ10's role in mitoc…
“you look at all your nutritional status right the B vitamins vitamin D vitamin E magnesium zinc copper CoQ10 lipoic acid Omega-3s”
CoQ10 is listed as a nutritional marker worth measuring when assessing overall health status, alongside other vitamins and nutrients.
“the cardiologists were recommending fish oil or CoQ10”
Cardiologists commonly recommend CoQ10 to their patients.
“CoQ10 is one of the supplements I think about seriously from a mitochondrial function standpoint, and it has particular clinical relevance for my patients who are on statins.”
CoQ10 is a supplement Attia thinks about seriously from a mitochondrial function standpoint, with particular clinical relevance for patients on statins.
The claim that CoQ10 has clinical relevance for mitochondrial function and statin patients is biologically plausible and broadly referenced in the literature. Several reviews in this set (PMID 2438920…
“CoQ10 is one of the supplements I think about seriously from a mitochondrial function standpoint, and it has particular clinical relevance for my patients who are on statins.”
CoQ10 is a supplement Attia thinks about seriously from a mitochondrial function standpoint, with particular clinical relevance for patients on statins.
The published research provided includes relevant reviews on CoQ10 (PMIDs 33325173, 24389208, 37971634, 34129891, 35199552, 32933108), which collectively support the biological plausibility of CoQ10's…
“CoQ10 is one of the supplements I think about seriously from a mitochondrial function standpoint, and it has particular clinical relevance for my patients who are on statins.”
CoQ10 is a supplement Attia thinks about seriously from a mitochondrial function standpoint, with particular clinical relevance for patients on statins.
The provided research includes reviews and meta-analyses that address CoQ10's role in mitochondrial function and clinical applications (PMIDs 24389208, 34129891, 33325173), which broadly supports the…
“the cardiologists were recommending fish oil or CoQ10”
Cardiologists commonly recommend CoQ10 to their patients.
“CoQ10 is one of the supplements I think about seriously from a mitochondrial function standpoint, and it has particular clinical relevance for my patients who are on statins.”
CoQ10 is a supplement Attia thinks about seriously from a mitochondrial function standpoint, with particular clinical relevance for patients on statins.
The claim that CoQ10 has clinical relevance for mitochondrial function is directly supported by multiple reviews (PMIDs 32933108, 35199552, 24389208) confirming CoQ10's essential role in mitochondrial…
“CoQ10 is one of the supplements I think about seriously from a mitochondrial function standpoint, and it has particular clinical relevance for my patients who are on statins.”
CoQ10 is a supplement Attia thinks about seriously from a mitochondrial function standpoint, with particular clinical relevance for patients on statins.
The published research provided includes reviews and meta-analyses covering CoQ10's role in mitochondrial disorders (PMID: 32933108), cardiovascular disease prevention (PMID: 37971634), neurological d…
“CoQ10 is one of the supplements I think about seriously from a mitochondrial function standpoint, and it has particular clinical relevance for my patients who are on statins.”
CoQ10 is a supplement Attia thinks about seriously from a mitochondrial function standpoint, with particular clinical relevance for patients on statins.
The provided literature confirms that CoQ10 has recognized roles in mitochondrial function and has clinical relevance across multiple conditions, including cardiovascular disease (PMID: 37971634) and…